Drs. Koshkin and Nizam discuss how a longer treatment-free interval may predict benefit from pembrolizumab rechallenge.
Urothelial Carcinoma
Advertisement
Latest News
Drs. Koshkin and Nizam break down recent research on pembro in patients with la/mUC who responded to first-course pembro.
Dr. Koshkin highlights emerging data on Nectin-4–targeted imaging and radiopharmaceuticals in urothelial cancer.
Dr. Koshkin shares an overview of FAP-targeted theranostics, including UCSF-led studies showing FAP PET imaging’s ability.
Dr. Grivas provides perspective of the long-term outcomes from the JAVELIN Bladder 100 trial as pertaining to older patients.
At the time of a pre-specified interim analysis, significant improvements in EFS and OS were seen.
Dr. Tyson discusses real-world decision-making around bladder-sparing options for BCG-unresponsive NMIBC.
Urothelial Carcinoma Knowledge Hubs
Curated clinical content based on urothelial cancer types, therapies, and technologies
Conference Coverage
Dr. Hong reviews relevant key findings from clinical trials for oligometastatic disease.
Dr. Hong reviews the criteria used to determine which patients may benefit from MDT.
Dr. Chu highlights how PSMA PET is transforming perioperative prostate cancer care, including improving surgical precision.
Dr. Koshkin highlights emerging data on Nectin-4–targeted imaging and radiopharmaceuticals in urothelial cancer.
Dr. Koshkin shares an overview of FAP-targeted theranostics, including UCSF-led studies showing FAP PET imaging’s ability.
Dr. Tagawa compares the use of PSMA-targeted antibodies to other treatment approaches such as radioligand therapy.
Advertisement
Advertisement
Latest News
An exploratory analysis revealed a strong OS advantage associated with a PD-L1 combined positive score higher than 1.
Drs. Koshkin and Nizam break down recent research on pembro in patients with la/mUC who responded to first-course pembro.
The combination of ADT and radiotherapy can provide quick benefits in patients with intermediate- or high-risk localized PCa.
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.